Can he pick them? A high-profile Wall Street analyst jumps into biotech as CFO of an oncology upstart
After spending the last decade building his rep as a biotech analyst at Jefferies, Biren Amin dropped word earlier in the week that he’s surfaced in a new job as CFO of a small, and still private, preclinical oncology biotech called Immuneering.
Amin has had plenty to say over the years about the oncology class of biotechs, a particularly hot property on Wall Street — especially during the boom IPO era we’ve been seeing in recent years. Now he’s making a flip over to a company where he’ll have a lot to say to insiders about the internal numbers.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 105,200+ biopharma pros reading Endpoints daily — and it's free.